This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...
This $1,585,446 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to develop a "nano scavenger" diagnostic and therapeutic agent for Parkinson's disease (PD). The research, conducted by Baylor College of Medicine, aims to validate the preclinical potential of a liposome-based agent that binds to oligomeric alpha-synuclein in...
This $1,009,212 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research into a novel gene therapy approach to reduce neurotoxicity in Parkinson's disease. The primary awardee, Van Andel Research Institute (VAI), will conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to develop a gene therapy that aims to enhance the...
This Project Grant award of $1,693,159, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research into the role of N-terminal acetylation (ACN) in regulating alpha-synuclein (AS) stability, function, and therapeutic targeting for synucleinopathies such as Parkinson's disease (PD) and Alzheimer's disease-related dementias (ADRD). The research aims...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to identify changes in synaptic vesicle-binding of alpha-synuclein as an early biomarker for Parkinson's disease (PD) and Alzheimer's disease related dementias (ADRD). The $793,535 award, with a project period from December 1, 2024 to November 30, 2029, will fund studies...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA program 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders, provides $670,600 to The Johns Hopkins University to conduct research on the role of microglia in Parkinson's disease (PD) cognitive and motor impairment. The research aims to better understand the relationship between a microglial-specific radioligand, [11C]CPPC, and the severity of...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop analytical approaches to determine how zinc's (Zn2+) ability to modulate dopamine (DA) release and uptake is affected in Alzheimer's disease (AD) and Parkinson's disease (PD). The total award of $661,537 was made on December 15, 2024 to the University of Kansas Center for Research Inc. The project will utilize fast-scan cyclic voltammetry combined with light-induced release of...
This federal Project Grant award of $2,208,982 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the role of the interleukin-13 receptor in Parkinson's disease. The research aims to determine the molecular and cellular mechanisms by which activation of the interleukin-13 receptor alpha 1 (IL-13RA1) can affect the survival of dopaminergic...
The National Institute on Aging (NIA) awarded a $1,512,892 Project Grant under the Aging Research program (CFDA 93.866) to 3P Biotechnologies, Inc. to develop a targeted nanoformulation delivery system for the bioactive curcuminoids, curcumin and bisdemethoxycurcumin, to treat Alzheimer's disease (AD). The Phase I project aims to optimize exosome-based formulations of these compounds and assess their biodistribution and toxicity in mice, as well as determine the efficacy of folic...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $636,000 to the University of Pittsburgh to investigate the use of NOX2 small molecule inhibitors as a potential therapeutic strategy for treating Alzheimer's disease (AD). The researchers aim to evaluate the ability of two novel, orally bioavailable, and blood-brain barrier penetrant NOX2 inhibitors (CPP11G and CPP11H) to improve cerebrovascular blood flow, reduce amyloid-beta deposition, and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $1,434,495 to Neuronasal Inc. to develop a novel intranasal (IN) nose-to-brain (N2B) treatment option for Parkinson's disease (PD) using the antioxidant N-acetylcysteine (NAC). The primary objectives are to: 1) establish the regional and temporal bioavailability profile of 50 mg/kg IV NAC in PD patients, 2) compare the bioavailability and safety of 200 mg and 400 mg IN N2B NAC versus the IV dosage, and 3) confirm the safety and tolerability of an equally bioavailable IN N2B NAC dose. This research aims to circumvent the pharmacokinetic/pharmacodynamic limitations of current antioxidant therapies for PD by leveraging the nose-to-brain delivery approach to enhance NAC's neuroprotective effects. The award period is from Sep 25, 2024 to Aug 31, 2025.